
SIGY
Healthcare · Biotechnology · $151,184 market cap
$0.02800.00 (0.0%)Nov 13, 9:30 AM EST
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 21, 2025 | Time not confirmed | — | -0.42 | — |
| Feb 26, 2025 | Time not confirmed | — | -0.33 | — |
| Nov 29, 2024 | Time not confirmed | — | -0.94 | — |
| Aug 13, 2024 | Time not confirmed | — | -0.70 | — |
| May 14, 2024 | Time not confirmed | — | -0.62 | — |
| Feb 28, 2024 | Time not confirmed | — | -0.94 | — |
| Nov 15, 2023 | Time not confirmed | — | -0.82 | — |
| Aug 15, 2023 | Time not confirmed | — | -0.67 | — |
| May 16, 2023 | Time not confirmed | — | -1.39 | — |
| Mar 1, 2023 | Time not confirmed | — | -0.91 | — |
| Nov 15, 2022 | Time not confirmed | — | -0.78 | — |
| Aug 15, 2022 | Time not confirmed | — | -0.71 | — |
| Sep 30, 2021 | Time not confirmed | — | -0.02 | — |
Sigyn Therapeutics, Inc., a development-stage company, develops and sells medical devices to treat cancer and infectious disease disorders in the United States. Its lead product candidate is Sigyn therapy, a broad-spectrum blood purification technology designed to treat pathogen-associated inflammatory disorders, including endotoxemia and inflammation in end-stage renal disease patients, sepsis, community-acquired…
| Time not confirmed |
| — |
| -0.02 |
| — |
| Mar 31, 2021 | Time not confirmed | 0.00 | -0.01 | — |
| Dec 31, 2020 | Time not confirmed | — | -0.03 | — |
| Sep 30, 2020 | Time not confirmed | — | -0.59 | — |
| Jun 30, 2020 | Time not confirmed | — | -0.52 | — |
| Mar 31, 2020 | Time not confirmed | — | -0.50 | — |
| Dec 31, 2019 | Time not confirmed | — | 1.15 | — |
| Sep 30, 2019 | Time not confirmed | — | -0.26 | — |